Premium
Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma
Author(s) -
Marr Kristin,
Ronsley Rebecca,
Nadel Helen,
Douglas Kate,
Gershony Sharon,
Strahlendorf Caron,
Davis Jeffrey H.,
Deyell Rebecca J.
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28167
Subject(s) - medicine , ifosfamide , vinorelbine , gemcitabine , refractory (planetary science) , salvage therapy , regimen , autologous stem cell transplantation , oncology , transplantation , surgery , chemotherapy , etoposide , astrobiology , cisplatin , physics
We describe 12 pediatric patients (8‐16 years) with primary refractory ( N = 6) or first relapse ( N = 6) Hodgkin lymphoma (HL) treated with ifosfamide, gemcitabine, and vinorelbine (IGEV). The overall response rate to IGEV was 100%, with seven (58%) complete responses (CR) and five (42%) partial responses. Successful CD34 + stem cell mobilization was achieved in all patients. Following subsequent autologous stem cell transplantation, 10 patients (83%) achieved CR. At a median follow‐up of 71 months, 11 patients had no evidence of disease. Five‐year second event‐free survival and overall survival were 83% ± 11.0% and 90.0% ± 9.5%, respectively. IGEV is an effective salvage regimen for children with relapsed/refractory HL.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom